AbbVie Inks Humira IP Licensing Deal With Samsung Bioepis
Pharmaceutical giant AbbVie on Thursday said it inked a deal to license the intellectual property of its Humira drug to Samsung Bioepis and to dismiss all related suits against the Samsung...To view the full article, register now.
Already a subscriber? Click here to view full article